|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.South Korea | 
| First Approval Date01 May 2008 | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| Drug Highest PhasePhase 2 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
|  | 
| Active Org.- | 
|  | 
| Active Indication- | 
|  | 
| Drug Highest PhasePending | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.
Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named [18F] LBT-999 in brain imaging compared to the SPECT reference method named [123I]-FP-CIT to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.
100 Clinical Results associated with Zionexa SAS
0  Patents (Medical) associated with Zionexa SAS
100 Deals associated with Zionexa SAS
100 Translational Medicine associated with Zionexa SAS